BiliaryTractCancer near Englewood, NJ

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Kazuki N. Sugahara, MD, PhD, is an Assistant Professor of Surgery. Dr. Sugahara studies drug delivery systems to enhance the diagnosis and therapy of various cancers, particularly pancreatic cancer. He has developed various tumor-targeting peptides that deliver compounds selectively to cancer tissue, and reported them in a number of high-profile journals such as Science. One of his peptides, the iRGD tumor-penetrating peptide, is now in a first-in-human Phase 1 clinical trial for metastatic pancreatic cancer. Dr. Sugahara's work has been recognized through grants and awards from national agencies such as the NIH, Department of Defense, and Pancreatic Cancer Action Network, and also from international societies such as the Japan Society of Drug Delivery Systems. After receiving his medical degree from Shiga University of Medical Science in Japan, Dr. Sugahara underwent surgery residency at Tazuke Kofukai Kitano Hospital, Osaka, Japan, received a PhD in cancer biology and immunology from the Osaka University Graduate School of Medicine, Japan, and completed a postdoctoral fellowship at the Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, California. He came to Columbia University in 2013 to take dual appointment as a categorical resident and a research faculty at the Department of Surgery. He now continues to pursue his career as a surgeon scientist with a special focus on pancreatic cancer.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Amengual is the Herbert Irving Associate Professor of Medicine in the Division of Hematology and Oncology, Center for Lymphoid Malignancies, and Hebert Irving Comprehensive Cancer Center here at Columbia University Irving Medical Center. Dr. Amengual obtained a degree in Nutritional Sciences at Cornell University where she graduated with honors. She attained her Medical Doctorate from New York Medical College, followed by a residency in Internal Medicine at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Amengual then went on to complete her fellowship in Hematology and Oncology at the NYU Langone Medical Center, where she participated in the Physician-Scientist Training Program and graduated as a Dean's Scholar. She is the recipient of several awards and scholarships for her research, including the Irving Scholarship, the Gabrielle's Angel Foundation for Cancer Research and as a Scholar of the Amos Medical Faculty Development Award Robert Wood Johnson Foundation and the American Society of Hematology. She was also selected to participate in the prestigious American Association for Cancer Research (AACR)/American Society of Clinical Oncology (ASCO) Vail Workshop Methods in Clinical Cancer Research, the European Hematology Association/American Society of Hematology Translational Research Training Program and the South West Oncology Group (SWOG) Leadership Academy. These competitive programs select the most promising faculty for enriched development and have laid the foundation for her research. She has now served on the faculty or review committee of several of these programs. As an R01-funded physician-scientist, Dr. Amengual is focused on translating the latest scientific discoveries regarding cancer cell behavior into novel treatment platforms. She aims to translate observations and concepts developed in the laboratory directly into patient care. Specifically, she is focused on combination epigenetic targeting for both B-cell and T-cell lymphomas. She continues to develop new pharmacologic strategies directed at altering these diseases at their genetic roots, now collaborating with investigators from backgrounds of diverse scientific expertise. Dr. Amengual has been studying the effects HDAC inhibitors in combination with EZH2 inhibitors to capitalize on two common mutations driving growth of diffuse large B-cell lymphoma cells. In addition, she has studied targeting the BCL6:p53 pathway in order to shift the balance of oncogene and tumor suppressor function using novel therapeutic approaches. For T-cell lymphoma Dr. Amengual has led a clinical trial combining HDAC inhibitors with the novel antifolate drug, pralatrexate. The pralatrexate plus romidepsin combination has led to dramatic responses in patients with relapsed T-cell lymphoma and will serve as the basis of more trials to come aimed at improving outcomes with patients with these diseases. Building on these discoveries, Dr. Amengual is now evaluating the interplay of epigenetics with immune surveillance and endogenous retroviral expression in the setting of lymphoma. Dr. Amengual has lectured at academic institutions and conferences around the world, and at forums such as the Lymphoma Research Foundation and the American Hematology Society's Highlights of ASH. She has published numerous chapters and peer reviewed articles on the biology and treatment of lymphoma, and serves as a Scientific Reviewer for a number of journals in the field, including Journal of Clinical Oncology and as an Editorial Board Member of Clinical Cancer Research. She has sat on grant review and abstract review committees for meetings such as the American Society of Hematology where she has also chaired sessions, American Society of Clinical Oncology and the Doris Duke Charitable Foundation. She is actively involved in the NCI's National Clinical Trial Network, SWOG, as a Lymphoma Working Group Committee Member. Dr. Amengual is involved in numerous clinical trials for lymphoma, enabling our patients to access the best opportunities for the treatment of their disease. Dr. Amengual has clinical expertise in lymphoma, HIV- and EBV-related hematologic illnesses.

Biography: Eileen Connolly, M.D., Ph.D. is Assistant Professor of Radiation Oncology at New York Presbyterian/Columbia University Medical Center. She is a board-certified radiation oncologist who cares for patients with all types of cancer but specializes in the treatment of breast and pediatric malignancies with radiation therapy. Dr. Connolly has published various articles in her field, including several related to breast cancer. In addition to her breast research she participates in a number of Children's Oncology Group (COG) protocols for the treatment of pediatric malignancies and works closely with the Pediatric Oncology group at Morgan Stanley Children's Hospital of New York-Presbyterian/Columbia University Medical Center. Dr. Connolly received her M.D./Ph.D. degree, internal medicine and radiation oncology training at New York University School of Medicine, where she was Chief Resident of Radiation Oncology. During her residency training she received both the 2010 Varian Medical Systems/RSNA Research Resident Grant and the 2010 ASTRO Residents/Fellows in Radiation Oncology Award. In addition, Dr. Connolly was trained in Gamma Knife Radiosurgery at the University of Pittsburgh Medical Center - Center for Image-Guided Neurosurgery, pioneers in the field of stereotactic radiosurgery for brain cancers and malformations. Besides her clinical duties Dr. Connolly is the director of a translational research laboratory in the Center for Radiological Research (CRR) in which she pursues her research interests in understanding the mechanisms of radiation resistance of cancer. Specifically her work focuses on the PI3K/Akt pathway with a goal of developing targeted agents that may be used as radiation sensitizers to reduce the risk of local recurrence. For her research she has received the 2012 Radiological Society of North America (RSNA) Research Seed grant, and a 2012 Irving Institute/Clinical Trials Office Pilot Award.

Biography: Dr. Ryan Moy is an Assistant Professor of Medicine and medical oncologist at Columbia University Irving Medical Center where he specializes in the treatment of gastrointestinal malignancies, with a focus on esophageal and stomach cancers. He received his MD/PhD from the University of Pennsylvania and completed internship and residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He then completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center and postdoctoral research at The Rockefeller University. Dr. Moy is actively involved in translational research to understand the biological mechanisms that regulate metastasis, the primary driver of mortality in gastrointestinal cancers. He has performed laboratory-based research to define critical genes that promote liver metastasis in colorectal cancer. He is also conducting research to discover key vulnerabilities in esophageal and gastric cancers, with the goal of translating these findings from the lab to develop more effective treatments for patients. As an active member of the gastrointestinal oncology and experimental therapeutics groups, Dr. Moy is involved in developing and leading clinical trials investigating novel targeted and immunotherapy treatments for esophagogastric cancer and other malignancies. His work has been recognized by several awards including a Damon Runyon Cancer Research Foundation Fellow Award and a National Cancer Institute (NCI) K08 Career Development Award. Dr. Moy works as part of a multidisciplinary team with the mission of delivering compassionate and state-of-the-art oncologic care to each patient, using a precision medicine approach to provide innovative and promising treatments.